Results 11 to 20 of about 7,099 (210)
Real-world impact of switching from tenofovir disoproxil fumarate to tenofovir alafenamide [PDF]
Drugs in Context, 2021 Although tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) have been evaluated in various clinical trials, limited safety and efficacy data exist in real-world settings.
Sarah M Michienzi +6 more
doaj +3 more sources
Co-crystals, Salts or Mixtures of Both? The Case of Tenofovir Alafenamide Fumarates
Pharmaceutics, 2020 Tenofovir alafenamide fumarate (TAF) is the newest prodrug of tenofovir that constitutes several drug products used for the treatment of HIV/AIDS. Although the solid-state properties of its predecessor tenofovir disoproxil fumarate have been investigated
Hannes Lengauer +7 more
doaj +4 more sources
A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide [PDF]
Journal of the International Association of Providers of AIDS Care, 2020 HIV is a serious chronic medical condition. Significant improvements in antiretroviral therapy have led to a transformation in its management. No curative treatment is available for HIV, and lifelong therapy is required with a combination of agents to ...
Chanie Wassner PharmD, BCCCP, BCIDP +2 more
doaj +3 more sources
CPT: Pharmacometrics & Systems Pharmacology, 2023 Tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) are prodrugs of the nucleotide analogue tenofovir, which acts intracellularly to inhibit HIV replication.
Aida N. Kawuma +8 more
doaj +3 more sources
Chiral Analysis of the Key Intermediates of Tenofovir Alafenamide Fumarate
Pharmaceutical Fronts, 2023 (R)-Tenofovir phenyl ester ((R)-1) and (R)-tenofovir diphenyl ester ((R)-2) are key intermediates for the practical synthesis of tenofovir alafenamide fumarate, which is a mainstay antiretroviral for the treatment of chronic hepatitis B and HIV-1 ...
Man Li, Ting Zhou, Qing-Wen Zhang
doaj +2 more sources
Journal of Virus Eradication, 2018 Background: Higher plasma tenofovir concentrations are associated with higher risks of renal and bone adverse events. The pharmacokinetic boosters ritonavir (RTV) and cobicistat (COBI) significantly increase plasma area under the curve (AUC ...
Andrew Hill +3 more
doaj +3 more sources
Successful Treatment of Progressive Multifocal Leukoencephalopathy With Tenofovir Alafenamide Fumarate. [PDF]
Neurol Neuroimmunol NeuroinflammProgressive multifocal leukoencephalopathy (PML) is a rare, often fatal CNS infection caused by reactivation of JC virus, typically in immunocompromised patients. No effective antiviral therapy has been established. We report a case of PML in a patient with multiple sclerosis (MS) treated with fingolimod, who received oral tenofovir alafenamide ...
Torkildsen Ø +3 more
europepmc +4 more sources
Interspecies Differences in Tenofovir Alafenamide Fumarate Stability in Plasma. [PDF]
Antimicrob Agents Chemother, 2020 Tenofovir (TFV) alafenamide fumarate (TAF) is an antiretroviral that has been evaluated in alternative drug delivery systems in several species. The ex vivo stability of TAF was evaluated, and TAF was stable in dog-, sheep-, and macaque-spiked plasma.
Parsons TL, Gwenden KN, Marzinke MA.
europepmc +4 more sources
Point-of-care semi-quantitative test for adherence to tenofovir alafenamide or tenofovir disoproxil fumarate [PDF]
Journal of Antimicrobial Chemotherapy, 2021 Abstract Objectives Objective measurement of antiretrovirals may aid clinical interventions for improving adherence to HIV prevention or treatment regimens. A point-of-care urine test could provide real-time information about recent adherence to regimens containing tenofovir disoproxil fumarate
Derin Sevenler +6 more
openaire +2 more sources
Molecules, 2021 Nucleoside and nucleotide analogues are essential antivirals in the treatment of infectious diseases such as human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), herpes simplex virus (HSV), varicella-zoster virus (VZV ...
Guangdi Li +5 more
doaj +1 more source